<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>GRISEOFULVIN - griseofulvin suspension </strong><br>Physicians Total Care, Inc.<br></p></div>
<h1></h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Griseofulvin is an antibiotic derived from a species of <span class="Italics">Penicillium</span>. Each 5 mL of Griseofulvin Oral Suspension 
(microsize) contains 125 mg of griseofulvin microsize and also contains alcohol 
0.2%, docusate sodium, FD&amp;C Red No. 40, FD&amp;C Yellow No. 6, flavors, 
magnesium aluminum silicate, menthol, methylparaben, propylene glycol, 
propylparaben, saccharin sodium, simethicone emulsion, sodium alginate, sucrose, 
and purified water. </p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Griseofulvin Oral Suspension acts systemically to inhibit the 
growth of <span class="Italics">Trichophyton, Microsporum</span>, and <span class="Italics">Epidermophyton</span> genera of fungi. Fungistatic amounts are 
deposited in the keratin, which is gradually exfoliated and replaced by 
noninfected tissue. </p>
<p>Griseofulvin absorption from the gastrointestinal tract varies considerably 
among individuals, mainly because of insolubility of the drug in aqueous media 
of the upper G.I. tract. The peak serum level found in fasting adults given 0.5 
gm occurs at about four hours and ranges between 0.5 and 2.0 mcg/mL.</p>
<p>It should be noted that some individuals are consistently "poor absorbers" 
and tend to attain lower blood levels at all times. This may explain 
unsatisfactory therapeutic results in some patients. Better blood levels can 
probably be attained in most patients if administered after a meal with a high 
fat content. </p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-3"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Major indications for Griseofulvin Oral Suspension are: </p>
<p><span class="product-label-link" type="condition" conceptid="4182398" conceptname="Tinea capitis">Tinea capitis</span> (ringworm of the scalp) </p>
<p><span class="product-label-link" type="condition" conceptid="135473" conceptname="Dermatophytosis">Tinea</span> corporis (ringworm of the body) </p>
<p><span class="product-label-link" type="condition" conceptid="133141" conceptname="Tinea pedis">Tinea pedis</span> (athlete's foot) </p>
<p><span class="product-label-link" type="condition" conceptid="135473" conceptname="Dermatophytosis">Tinea</span> unguium (<span class="product-label-link" type="condition" conceptid="4215978" conceptname="Onychomycosis">onychomycosis</span>; ringworm of the nails) </p>
<p><span class="product-label-link" type="condition" conceptid="4160328" conceptname="Tinea cruris">Tinea cruris</span> (ringworm of the thigh) </p>
<p><span class="product-label-link" type="condition" conceptid="135473" conceptname="Dermatophytosis">Tinea</span> barbae (barber's <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itch</span>) </p>
<p>Griseofulvin Oral Suspension inhibits the growth of those genera of fungi 
that commonly cause ringworm <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> of the hair, skin, and nails, such as: 
</p>
<p><span class="Italics">Trichophyton rubrum </span></p>
<p><span class="Italics">Trichophyton tonsurans </span></p>
<p><span class="Italics">Trichophyton mentagrophytes </span></p>
<p><span class="Italics">Trichophyton interdigitalis </span></p>
<p><span class="Italics">Trichophyton verrucosum </span></p>
<p><span class="Italics">Trichophyton sulphureum </span></p>
<p><span class="Italics">Trichophyton schoenleini </span></p>
<p><span class="Italics">Microsporum audouini </span></p>
<p><span class="Italics">Microsporum canis </span></p>
<p><span class="Italics">Microsporum gypseum </span></p>
<p><span class="Italics">Epidermophyton floccosum </span></p>
<p><span class="Italics">Trichophyton megnini </span></p>
<p><span class="Italics">Trichophyton gallinae </span></p>
<p><span class="Italics">Trichophyton crateriform </span></p>
<p><span class="Italics">Note:</span> Prior to therapy, the type of fungi 
responsible for the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> should be identified. The use of the drug is not 
justified in minor or trivial <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> which will respond to topical 
anti-fungal agents alone. </p>
<p>It is <span class="Italics">not</span> effective in: </p>
<p><span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">Bacterial infections</span> </p>
<p><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candidiasis</span> (<span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Moniliasis</span>) </p>
<p><span class="product-label-link" type="condition" conceptid="433134" conceptname="Histoplasmosis">Histoplasmosis</span></p>
<p><span class="product-label-link" type="condition" conceptid="436020" conceptname="Actinomycotic infection">Actinomycosis</span> </p>
<p>Sporotrichosis </p>
<p>Chromoblastomycosis </p>
<p><span class="product-label-link" type="condition" conceptid="437217" conceptname="Coccidioidomycosis">Coccidioidomycosis</span> </p>
<p>North American <span class="product-label-link" type="condition" conceptid="433146" conceptname="Blastomycosis">Blastomycosis</span> </p>
<p><span class="product-label-link" type="condition" conceptid="440035" conceptname="Cryptococcosis">Cryptococcosis</span> (Torulosis) </p>
<p><span class="product-label-link" type="condition" conceptid="134870" conceptname="Pityriasis versicolor">Tinea versicolor</span> </p>
<p><span class="product-label-link" type="condition" conceptid="4104668" conceptname="Nocardiosis">Nocardiosis</span> </p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">This drug is contraindicated in patients with <span class="product-label-link" type="condition" conceptid="4305376" conceptname="Porphyria">porphyria</span>, 
hepatocellular failure, and in individuals with a history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to 
griseofulvin. </p>
<p>Two cases of conjoined twins have been reported in patients taking 
griseofulvin during the first trimester of pregnancy. Griseofulvin should not be 
prescribed to pregnant patients. </p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="section-5"></a><p></p>
<h1>WARNINGS</h1>
<a href="http://"></a><span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">Prophylactic</span> Usage<p class="First">Safety and efficacy of <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> use of Griseofulvin Oral 
Suspension has not been established. </p>
<p>Chronic feeding of griseofulvin, at levels ranging from 0.5-2.5% of the diet, 
resulted in the development of <span class="product-label-link" type="condition" conceptid="4322895" conceptname="Nodule of liver">liver tumors</span> in several <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of mice, 
particularly in males. Smaller particle sizes result in an enhanced effect. 
Lower oral dosage levels have not been tested. Subcutaneous administration of 
relatively small doses of griseofulvin once a week during the first three weeks 
of life has also been reported to induce hepatomata in mice.Although studies in 
other animal species have not yielded evidence of tumorigenicity, these studies 
were not of adequate design to form a basis for conclusions in this regard. </p>
<p>In subacute toxicity studies, orally administered griseofulvin produced 
hepatocellular <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span> in mice, but this has not been seen in other species. 
Disturbances in porphyrin metabolism have been reported in griseofulvin-treated 
laboratory animals. Griseofulvin has been reported to have a colchicine-like 
effect on mitosis and cocarcinogenicity with methylcholanthrene in cutaneous 
tumor induction in laboratory animals. </p>
<p>Reports of animal studies in the Soviet literature state that a griseofulvin 
preparation was found to be embryotoxic and teratogenic on oral administration 
to pregnant Wistar rats. Rat reproduction studies done in the United States and 
Great Britain were inconclusive in this regard. Pups with abnormalities have 
been reported in the litters of a few bitches treated with griseofulvin. Because 
the potential for adverse effects on the human fetus cannot be ruled out, 
additional contraceptive precautions should be taken during treatment with 
griseofulvin and for a month after termination of treatment. Griseofulvin Oral 
Suspension should not be prescribed to women intending to become pregnant within 
one month following cessation of therapy. </p>
<p>Suppression of spermatogenesis has been reported to occur in rats but 
investigation in man failed to confirm this. Griseofulvin interferes with 
chromosomal distribution during cell division, causing aneuploidy in plant and 
mammalian cells. These effects have been demonstrated <span class="Italics">in 
vitro</span> at concentrations that may be achieved in the serum with the 
recommended therapeutic dosage. </p>
<p>Since griseofulvin has demonstrated harmful effects <span class="Italics">in 
vitro</span> on the genotype in bacteria, plants, and fungi, males should wait 
at least six months after completing griseofulvin therapy before fathering a 
child. </p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-6"></a><p></p>
<h1>PRECAUTIONS</h1>
<p class="First">Patients on prolonged therapy with any potent medication should 
be under close observation. Periodic monitoring of organ system function, 
including renal, hepatic and hemopoietic, should be done. </p>
<p>Since griseofulvin is derived from species of penicillin, the possibility of 
cross sensitivity with penicillin exists; however, known penicillin-sensitive 
patients have been treated without difficulty. </p>
<p>Since a <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity reaction</span> is occasionally associated with 
griseofulvin therapy, patients should be warned to avoid exposure to intense 
natural or artificial sunlight. Should a <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity reaction</span> occur, lupus 
erythematosus may be aggravated.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section-7"></a><p></p>
<h1>DRUG INTERACTIONS</h1>
<p class="First">Patients on warfarin-type anticoagulant therapy may require 
dosage adjustment of the anticoagulant during and after griseofulvin therapy. 
Concomitant use of barbiturates usually depresses griseofulvin activity and may 
necessitate raising the dosage. </p>
<p>The concomitant administration of griseofulvin has been reported to reduce 
the efficacy of oral contraceptives and to increase the incidence of 
breakthrough <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. </p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">When adverse reactions occur, they are most commonly of the 
<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> type such as <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rashes</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span> and rarely, angioneurotic 
<span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> or <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>-like drug reaction, and may necessitate withdrawal 
of therapy and appropriate countermeasures. <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">Paresthesias</span> of the hands and feet 
have been reported rarely after extended therapy. Other side effects reported 
occasionally are <span class="product-label-link" type="condition" conceptid="29735" conceptname="Candidiasis of mouth">oral thrush</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">epigastric distress</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, 
<span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">mental confusion</span> and impairment of 
performance of routine activities. </p>
<p><span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">Proteinuria</span> and <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span> have been reported rarely. Administration of the 
drug should be discontinued if <span class="product-label-link" type="condition" conceptid="4218497" conceptname="Granulocytopenic disorder">granulocytopenia</span> occurs. </p>
<p>When rare, serious reactions occur with griseofulvin, they are usually 
associated with high dosages, long periods of therapy, or both. </p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-9"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">Accurate diagnosis of the infecting organism is essential. 
Identification should be made either by direct microscopic examination of a 
mounting of infected tissue in a solution of potassium hydroxide or by culture 
on an appropriate medium.</p>
<p>Medication must be continued until the infecting organism is completely 
eradicated as indicated by appropriate clinical or laboratory examination. 
Representative treatment periods are <span class="product-label-link" type="condition" conceptid="4182398" conceptname="Tinea capitis">tinea capitis</span>, 4 to 6 weeks; <span class="product-label-link" type="condition" conceptid="135473" conceptname="Dermatophytosis">tinea</span> 
corporis, 2 to 4 weeks; <span class="product-label-link" type="condition" conceptid="133141" conceptname="Tinea pedis">tinea pedis</span>, 4 to 8 weeks; <span class="product-label-link" type="condition" conceptid="135473" conceptname="Dermatophytosis">tinea</span> unguium – depending on 
rate of growth – fingernails, at least 4 months; toenails, at least 6 
months.</p>
<p>General measures in regard to hygiene should be observed to control sources 
of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> or reinfection. Concomitant use of appropriate topical agents is 
usually required, particularly in treatment of <span class="product-label-link" type="condition" conceptid="133141" conceptname="Tinea pedis">tinea pedis</span> since in some forms 
of athlete's foot, yeasts and bacteria may be involved. Griseofulvin will not 
eradicate the bacterial or monilial <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. </p>
<a href="http://"></a><a href="http://"></a>Adults<p>A daily dose of 500 mg will give a satisfactory response in most 
patients with <span class="product-label-link" type="condition" conceptid="135473" conceptname="Dermatophytosis">tinea</span> corporis, <span class="product-label-link" type="condition" conceptid="4160328" conceptname="Tinea cruris">tinea cruris</span>, and <span class="product-label-link" type="condition" conceptid="4182398" conceptname="Tinea capitis">tinea capitis</span>. </p>
<p>For those fungus <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> more difficult to eradicate such as <span class="product-label-link" type="condition" conceptid="133141" conceptname="Tinea pedis">tinea pedis</span> 
and <span class="product-label-link" type="condition" conceptid="135473" conceptname="Dermatophytosis">tinea</span> unguium, a daily dose of 1.0 gram is recommended. </p>
<a href="http://"></a><a href="http://"></a>Children<p>Approximately 5 mg per pound of body weight per day is an 
effective dose for most children. On this basis the following dosage schedule 
for children is suggested: </p> Children weighing 30 to 50 pounds – 125 mg to 250 mg daily.  Children weighing over 50 pounds – 250 mg to 500 mg daily. </div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-10"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Griseofulvin Oral Suspension 125 mg per 5 mL in bottles of 4 fl 
oz (120 mL) (<span class="Bold">NDC 54868-5234-0</span>). </p>
<p>Dispense Griseofulvin Oral Suspension in a tight, light-resistant container 
as defined in the USP. </p>
<a href="http://"></a><a href="http://"></a><p>STORE AT ROOM TEMPERATURE </p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.1"></a><p></p>
<p class="First">For more information call 1-800-510-0383. </p>
<p>Manufactured by: <br>Ortho-McNeil Pharmaceutical, Inc. <br>Raritan, NJ 08869 
</p>
<p>Distributed by: <br>Patriot Pharmaceuticals, LLC <br>Plymouth Meeting, PA 
19462 </p>
<p>Printed in U.S.A., © OMP 2005 </p>
<p>Revised July 2005 <br>10094000 <br></p>
<br><p><span class="Bold">Relabeling of "Additional Barcode Label" by:</span><br>Physicians Total Care, Inc.<br>Tulsa, OK     74146<br></p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-11"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 5 mL Label</h1>
<p class="First"><span class="Bold">Griseofulvin <br>Oral Suspension <br>(microsize)<br>125 mg/5 
mL</span></p>
<p>Each 5 mL (one teaspoonful) contains 125 mg <br>Griseofulvin microsize in a 
palatable suspension, <br>colored orange. Also contains alcohol 0.2%. <br><span class="Bold"></span></p>
<p><span class="Bold">Rx</span> Only. <br></p>
<p>Store at room temperature. <br><span class="Bold"></span></p>
<p><span class="Bold">SHAKE BEFORE USING</span><br></p>
<p>Pharmacist: This product is protected 
by a tamper- <br>resistant seal around the neck opening. If the seal <br>has 
been broken or is removed, <span class="Underline">do not use</span> the 
<br>product. Return the product to place of purchase.</p>
<p><span class="Bold">4 fl oz (120 mL)</span></p>
<p><img alt="image of package label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=82f52d21-eacd-4edf-8ad5-a8ef090ffa2a&amp;name=package%20label.jpg"><br><span class="Bold"></span></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>GRISEOFULVIN 		
					</strong><br><span class="contentTableReg">griseofulvin suspension</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-5234(NDC:10147-0810)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>GRISEOFULVIN</strong> (GRISEOFULVIN) </td>
<td class="formItem">GRISEOFULVIN</td>
<td class="formItem">125 mg  in 5 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>DOCUSATE SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C RED NO. 40</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C YELLOW NO. 6</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM ALUMINUM SILICATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MENTHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>METHYLPARABEN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>PROPYLENE GLYCOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PROPYLPARABEN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SACCHARIN SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM ALGINATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SUCROSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-5234-0</td>
<td class="formItem">120 mL in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA062483</td>
<td class="formItem">01/16/2006</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Physicians Total Care, Inc.
							(194123980)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Physicians Total Care, Inc.</td>
<td class="formItem"></td>
<td class="formItem">194123980</td>
<td class="formItem">relabel</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 10/2010<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>906db94a-6285-451c-a3a9-4b5da597eed1</div>
<div>Set id: 82f52d21-eacd-4edf-8ad5-a8ef090ffa2a</div>
<div>Version: 1</div>
<div>Effective Time: 20101025</div>
</div>
</div> <div class="DistributorName">Physicians Total Care, Inc.</div></p>
</body></html>
